Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


A Structure-Activity Relationship Study of Bis-Benzamides as Inhibitors of Androgen Receptor-Coactivator Interaction.

Lee TK, Ravindranathan P, Sonavane R, Raj GV, Ahn JM.

Molecules. 2019 Jul 31;24(15). pii: E2783. doi: 10.3390/molecules24152783.


Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells.

Ravindranathan P, Pasham D, Goel A.

Carcinogenesis. 2019 May 14;40(3):412-421. doi: 10.1093/carcin/bgy184.


A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer.

Ravindranathan P, Pasham D, Balaji U, Cardenas J, Gu J, Toden S, Goel A.

Sci Rep. 2018 Sep 14;8(1):13869. doi: 10.1038/s41598-018-32267-8.


A patient-derived explant (PDE) model of hormone-dependent cancer.

Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, Birrell SN, Knudsen KE, Raj GV, Butler LM, Tilley WD.

Mol Oncol. 2018 Sep;12(9):1608-1622. doi: 10.1002/1878-0261.12354. Epub 2018 Aug 16.


Mechanistic insights into anticancer properties of oligomeric proanthocyanidins from grape seeds in colorectal cancer.

Ravindranathan P, Pasham D, Balaji U, Cardenas J, Gu J, Toden S, Goel A.

Carcinogenesis. 2018 May 28;39(6):767-777. doi: 10.1093/carcin/bgy034.


Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer.

Toden S, Ravindranathan P, Gu J, Cardenas J, Yuchang M, Goel A.

Sci Rep. 2018 Feb 20;8(1):3335. doi: 10.1038/s41598-018-21478-8.


Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.

Yoshida K, Toden S, Ravindranathan P, Han H, Goel A.

Carcinogenesis. 2017 Oct 1;38(10):1036-1046. doi: 10.1093/carcin/bgx065.


Mouse Spermatogenesis Requires Classical and Nonclassical Testosterone Signaling.

Toocheck C, Clister T, Shupe J, Crum C, Ravindranathan P, Lee TK, Ahn JM, Raj GV, Sukhwani M, Orwig KE, Walker WH.

Biol Reprod. 2016 Jan;94(1):11. doi: 10.1095/biolreprod.115.132068. Epub 2015 Nov 25.


Minireview: Deciphering the Cellular Functions of PELP1.

Ravindranathan P, Lange CA, Raj GV.

Mol Endocrinol. 2015 Sep;29(9):1222-9. doi: 10.1210/me.2015-1049. Epub 2015 Jul 9. Review. No abstract available.


EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.

Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM.

Oncotarget. 2015 Feb 28;6(6):3811-24.


The social network of PELP1 and its implications in breast and prostate cancers.

Gonugunta VK, Miao L, Sareddy GR, Ravindranathan P, Vadlamudi R, Raj GV.

Endocr Relat Cancer. 2014 Aug;21(4):T79-86. doi: 10.1530/ERC-13-0502. Epub 2014 May 23. Review.


Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.

Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, Fazli L, Gleave ME, Plymate SR, Raj GV, Hsieh JT, Kittler R.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4251-6. doi: 10.1073/pnas.1322198111. Epub 2014 Mar 3.


Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.

Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA.

Oncogene. 2015 Jan 22;34(4):506-15. doi: 10.1038/onc.2013.579. Epub 2014 Jan 27.


Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.

Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV.

Nat Commun. 2013;4:1923. doi: 10.1038/ncomms2912.


Dual roles of PARP-1 promote cancer growth and progression.

Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE.

Cancer Discov. 2012 Dec;2(12):1134-49. doi: 10.1158/2159-8290.CD-12-0120. Epub 2012 Sep 19.


Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.

Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, Raj GV.

Mol Endocrinol. 2012 Apr;26(4):550-61. doi: 10.1210/me.2011-1101. Epub 2012 Mar 8.

Supplemental Content

Loading ...
Support Center